AI Agent Governance for Pharmacy Automation Systems

Why Pharmacy Automation Requires a Distinct Governance Model

AI agents deployed in pharmacy automation are increasingly assigned tasks that carry direct patient-safety and regulatory consequences: prescription verification, dosage calculation, inventory reconciliation, and data exchange with EHR and pharmacy management platforms. These are not low-risk background tasks. An agent with broad tool-call permissions that misinterprets a dosage input, reconciles inventory incorrectly, or acts outside its intended scope can produce consequences that fall under existing healthcare compliance obligations, even though no regulation was written with autonomous agents in mind. HIPAA's Security Rule requires audit controls over any system handling electronic protected health information, and HHS guidance has clarified that this obligation applies to AI tools processing ePHI regardless of whether a human or an agent performs the action. Similarly, the Drug Supply Chain Security Act requires verifiable, transaction-level traceability for prescription drug products, a requirement that extends to any AI-mediated inventory or product-identifier action. Pharmacy automation environments sit at the intersection of these obligations, but neither framework was designed to constrain agent behavior in real time. That gap is the starting point for governance design.

The Compliance Gap Between Existing Rules and Agentic Systems

HIPAA and DSCSA establish what must be protected and traced, not how an autonomous agent's real-time actions should be permitted, intercepted, or logged. NIST's AI Risk Management Framework offers a lifecycle structure (Govern, Map, Measure, Manage) for identifying and mitigating AI system risk, and its Generative AI Profile explicitly names risks relevant to agentic systems, including unauthorized data disclosure and value chain integration risks. These are useful reference points, but they are general-purpose frameworks, not pharmacy-specific mandates. FDA guidance on AI/ML-based software as a medical device addresses change control for algorithms that influence clinical decisions, but it does not address real-time tool invocation by an agent operating inside a pharmacy workflow. The practical implication for governance leaders is that compliance cannot be achieved by pointing to a single regulation. It requires mapping each agent's actual tool-call capabilities against HIPAA access-control requirements and DSCSA traceability obligations, then closing the gaps with architectural controls that neither framework specifies.

Architectural Requirements for Agent Identity and Scoping

Zero Trust principles, as described in NIST SP 800-207, provide the most directly applicable architectural reference for scoping AI agent access, even though the standard was not written for agentic AI specifically. Continuous verification of identity and enforcement of least privilege on every access request are the two principles that translate most directly into pharmacy automation environments.

Runtime Policy Enforcement in Practice

OWASP's Top 10 for Large Language Model Applications identifies excessive agency and insecure plugin design as concrete risks when agents are granted broad tool-call permissions. In a pharmacy context, excessive agency might look like an agent authorized to read inventory data also being able to initiate a dispensing action, or a verification agent gaining write access to a patient record it was only meant to read. Runtime policy enforcement addresses this by checking each proposed action against a defined permission set at the moment the action is attempted, not after the fact through log review.

This distinguishes runtime enforcement from static compliance controls: HIPAA audit controls and DSCSA transaction records establish what must be recorded, but they do not stop an out-of-scope action from occurring. A runtime enforcement point sits before the EHR interface or dispensing system, evaluates the requested action against the agent's scoped permissions, and blocks or escalates anything outside that scope. This is the architectural layer most current healthcare compliance frameworks assume exists but do not explicitly mandate.

Auditability and Decision-Level Logging

HIPAA's audit control requirement is often satisfied at the system access level: who logged in, what record was opened, when. For AI agents, this level of logging is insufficient for post-incident review or regulatory accountability. Logging architecture needs to capture the agent's decision context, including the input that triggered an action, the specific tool call made, and the output or system change that resulted.

This is a higher bar than typical system logs, and it is necessary because an agent's action is the product of an inference process, not a direct human command. NIST AI RMF guidance recommends maintaining documentation of AI system decisions to support traceability and accountability in high-risk deployment contexts, and dosage calculation, prescription verification, and inventory reconciliation all qualify as high-risk in a pharmacy setting. Where agents influence dispensing or dosage outcomes, FDA's software-as-a-medical-device guidance on change control provides a useful model: any update to agent logic that affects these decisions should go through a documented review process before deployment, not after an incident surfaces the change.

Common Questions on Pharmacy AI Agent Governance